What Престанс Н Treats: Main Uses and Benefits

Престанс Н is generally used for the long-term, stable management of essential hypertension, a condition characterized by persistently elevated blood pressure readings. The core benefit provides support for continuous control to support the reduction of elevated pressure readings, an action that supports the overall effort to manage systemic imbalance. Lowering blood pressure in this manner contributes to reducing cardiovascular risk.

The fixed-dose combination is commonly applied in clinical settings where a patient has an established high risk of cardiovascular events, such as a history of stroke or coronary artery disease, supporting the management of the patient's cardiovascular risk profile. The medicine is relevant in scenarios where a patient requires two distinct antihypertensive agents to support the reduction of elevated pressure readings. By combining both necessary components into a single tablet, the treatment helps simplify the daily regimen, which contributes to better patient adherence.

“The combination therapy is commonly used to help with managing functional stability and addressing symptom clusters that may become disruptive over time.”

---

Quick Fact: Relief for Elevated Blood Pressure

Official Eligibility and Contraindications

Престанс Н (a combination of perindopril, indapamide, and amlodipine) is designated as substitution therapy for adult patients whose blood pressure is already controlled by taking the individual components at the same dose levels.

Use of this medicine is strictly contraindicated (must not be used) under the following conditions as documented in official regulatory labeling:

• Hypersensitivity: Known allergy to perindopril (or any ACE inhibitor), indapamide (or any sulfonamide), amlodipine (or any dihydropyridine), or any inactive ingredient.
• Prior Reaction: A history of angioedema (severe swelling of the face, limbs, etc.) related or unrelated to previous ACE inhibitor use.
• Organ Dysfunction: Severe renal impairment (creatinine clearance below 30 mL/min) or severe hepatic impairment (risk of hepatic encephalopathy).
• Cardiac Status: Severe hypotension, shock, obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis), or untreated decompensated heart failure.
• Pregnancy and Lactation: Use is contraindicated during the second and third trimesters of pregnancy and not recommended during the first trimester or while breastfeeding.
• Drug-Drug Prohibitions: Concomitant use with Sacubitril/Valsartan (must wait 36 hours after the last dose) or with Aliskiren in patients with diabetes or moderate-to-severe kidney impairment.

Use Not Established: The safety and efficacy of this medicine have not been established for the paediatric population (children and adolescents under 18 years of age).

Interactions with other medicines and products

The following interaction information is based strictly on regulatory documents for the active components, Amlodipine and Perindopril. This summary focuses only on officially documented constraints and effects.

---

Formally Contraindicated Combinations

Interacting Agent	Constraint	Context/Restriction
Sacubitril/Valsartan	Co-administration is prohibited (due to angioedema risk).	A 36-hour separation period is required between the two agents.
Aliskiren	Co-administration is prohibited.	Constraint is specific to patients with diabetes mellitus.

---

Documented Pharmacodynamic and Metabolic Interactions

Combinations with the following substances are officially noted for specific risks, requiring cautious administration:

• Agents Increasing Potassium Levels: Concurrent use with Potassium-Sparing Diuretics (e.g., Spironolactone) or Potassium Supplements is documented to cause a risk of hyperkalaemia.
• CYP3A4 Inhibitors: Strong and moderate inhibitors (e.g., Ketoconazole, Diltiazem) are documented to increase the systemic exposure of Amlodipine.
• CYP3A4 Inducers: Strong inducers (e.g., Rifampicin, St. John’s Wort) are documented to potentially reduce the plasma concentration of Amlodipine.
• mTOR Inhibitors (e.g., Sirolimus): Documented increased risk of angioedema.
• Grapefruit/Grapefruit Juice: Documented potential to increase Amlodipine exposure.

---

Population-Specific Interaction Notes

The elimination of the active Perindopril metabolite is officially documented as decreased in elderly patients and those with impaired renal function, which may amplify the risk of certain pharmacodynamic interactions.

Престанс Н is a fixed-dose combination containing the prodrug perindopril and the thiazide-like diuretic indapamide.

Perindopril undergoes hepatic hydrolysis to form its active metabolite, perindoprilat. Perindoprilat acts as a competitive inhibitor of angiotensin-converting enzyme (ACE), an enzyme predominantly found on the luminal surface of vascular endothelial cells. By inhibiting ACE, the enzymatic cleavage of angiotensin I to the potent vasoconstrictor angiotensin II is reduced in the systemic circulation. This results in decreased angiotensin II-mediated vasoconstriction and diminished aldosterone secretion from the adrenal cortex. The downstream cascade involves a reduction in systemic vascular resistance and a decrease in sodium and water reabsorption in the distal nephron.

Indapamide acts at the proximal segment of the distal convoluted tubule within the kidney. It functions as an inhibitor of the Na^+/ Cl^- cotransporter (NCC). This molecular interaction blocks the reabsorption of sodium and chloride ions, leading to their increased delivery to the collecting duct and subsequent osmotic water excretion. This intracellular modification results in enhanced urinary sodium and water loss, leading to reduced plasma volume. Additionally, indapamide possesses peripheral effects that involve a reduction in vascular smooth muscle reactivity to vasoactive agents. The combined system-level physiological consequence of both components is a sustained decrease in total peripheral resistance and circulating volume.

How to Use Престанс Н

Престанс Н (Perindopril/Amlodipine/Hydrochlorothiazide) is a fixed-dose combination product containing three active substances in a single film-coated tablet. This medicine is intended for oral administration and must be used strictly according to the official prescribing information.

Administration Guidelines

Administration Scope	Official Instruction
Dosing Schedule	The recommended dose is one tablet per day.
Timing & Frequency	Take the tablet once daily, preferably in the morning and before a meal.
Tablet Handling	The tablet must be swallowed whole with a sufficient quantity of liquid. It must not be chewed or crushed.

Use Context and Dosage Adjustments

This medicine is designated as substitution therapy for adults. It is only appropriate for use in patients whose blood pressure is already adequately controlled by taking the same doses of perindopril, amlodipine, and hydrochlorothiazide as separate mono-preparations or dual-combination products.

The fixed-dose combination is not suitable for initiating therapy. If any change in dosage is required, the official instruction mandates that dose titration must be performed using the individual components separately before returning to a combination tablet.

Special populations: Dosage for elderly patients must be adjusted based on monitoring of renal function and blood pressure response. Use is contraindicated in severe renal impairment (creatinine clearance < 30 mL/min) and severe hepatic impairment.

Recent Clinical Evidence Overview

Prestans H is a fixed-dose combination therapy containing perindopril (an ACE inhibitor) and indapamide (a thiazide-like diuretic). The evidence base for this combination primarily supports its use in managing high blood pressure (hypertension).

---

Efficacy in Hypertension and Cardiovascular Outcomes

Clinical trials, including large-scale randomized studies, have investigated the effect of the perindopril/indapamide combination, especially in high-risk patient populations.

• Blood Pressure Reduction: Studies evaluated whether the combination was associated with a significant reduction in both systolic and diastolic blood pressure. Trials have reported findings consistent with normalization of blood pressure in a high percentage of patients with essential hypertension and isolated systolic hypertension.
• Long-Term Benefit: Pooled analyses of trials, which predominantly featured indapamide (often combined with perindopril), explored the association between treatment and long-term outcomes. Findings suggested a reduced risk of cardiovascular events, including stroke and cardiovascular death, in medium-to-high risk individuals.

---

Tolerability and Safety Findings

Research has explored the tolerability profile of the fixed-dose combination compared to individual components:

• Hypokalemia: The co-administration of perindopril and indapamide was examined for its effect on potassium levels. Evidence suggested that the combination may be associated with a reduced incidence of hypokalemia (low potassium) compared to indapamide when used alone.
• Adverse Events: Clinical trials reported that the combination generally had a tolerability profile similar to placebo, with most adverse events being mild to moderate in severity. Commonly reported effects included headache and gastrointestinal discomfort.

Common questions about Престанс Н (FAQ)

Q: What is Presance H prescribed for, besides high blood pressure?

Official product information describes the medicine primarily for managing high blood pressure (hypertension). Regulatory documents also indicate the drug is used for the treatment of stable coronary artery disease in patients who are adequately controlled on the constituent agents given separately.

---

Q: Is it true that Prestans H can affect the kidneys?

Official labeling includes cautionary notes regarding use in patients with impaired kidney function. The medicine is generally not recommended for those with severe kidney impairment (creatinine clearance < 30 mL/min). Use in patients with mild to moderate impairment requires careful medical oversight.

---

Q: Does Prestans H affect blood sugar levels?

Symptoms related to elevated blood sugar, such as increased thirst or frequent urination, are listed as potential, although infrequent, adverse reactions linked to the diuretic component. These symptoms should be reported to the prescribing physician.

---

Q: Do I need to follow a special diet while taking it?

Regulatory information notes specific interactions with grapefruit and grapefruit juice. Official warnings also advise against the use of salt substitutes that contain high levels of potassium. Aside from these specific substances, no other general food restrictions are typically mandated.

---

Q: Is Prestans H compatible with alcohol?

Alcohol consumption may lead to an additive effect that lowers blood pressure further than the medication alone. This effect can potentially cause symptoms like dizziness or lightheadedness, especially when treatment begins or following a dose change.

---

Q: Which over-the-counter painkillers can be taken with Prestans H?

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may interact and could potentially reduce the medicine's effectiveness in controlling blood pressure. Low-dose aspirin, typically 75 mg per day used for cardiovascular prevention, is generally noted in regulatory documents as less concerning than high-dose NSAIDs.

---

Q: What should I do if I miss a dose?

Official instructions advise taking the dose as soon as it is remembered, if feasible. However, if it is almost time for your next scheduled dose, regulatory guidelines specifically advise skipping the missed dose and continuing the regular schedule. Taking a double dose is strongly advised against.

---

Q: If I have diabetes, can I take Prestans H?

While the presence of diabetes itself is not an absolute contraindication, official documents state a specific contraindication against combining this medicine with the drug Aliskiren in diabetic patients. The use of this medication in patients with diabetes requires medical oversight.

---

Q: Which vitamins and supplements should not be taken with Prestans H?

Regulatory guidance stresses the importance of disclosing all substances to a healthcare provider, including all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. This is because safety data on every possible combination may be limited.

---

Q: What should I do if my blood pressure remains high?

If blood pressure remains high or is difficult to control, medical consultation is necessary. Official instructions state that any required dose adjustment must be performed using the individual drug components separately before re-initiating the fixed combination.

---

Q: How does Prestans H affect heart rate (pulse)?

Changes in pulse or heart rate, as well as an abnormal heartbeat (such as a pounding, slow, or fast pulse), are potential adverse effects listed in regulatory documents. Persistent changes in heart rhythm should be reported to the prescribing physician.

---

Q: Can I take this medicine if I work as a driver?

Since this drug can cause side effects like dizziness or lightheadedness, regulatory information advises that driving or operating hazardous machinery be avoided until the medication's effects on concentration and alertness are fully known.

---

Q: Does Prestans H affect body weight?

Rapid weight gain or noticeable swelling in the hands, ankles, or feet may indicate fluid retention, which is a common side effect of the diuretic component (edema). This change should be reported to the treating physician promptly.

---

Q: How does Prestans H interact with cold medicines?

Regulatory caution exists because many common over-the-counter cold and flu preparations contain ingredients that can potentially raise blood pressure. These substances may interfere with the effectiveness of your anti-hypertensive drug, meaning professional guidance is necessary before use.

---

Q: What happens if I accidentally take two tablets instead of one?

Official guidance strictly advises against taking a double or extra dose. In the event of suspected overdosage, regulatory guidance directs immediate contact with emergency medical services or a poison control center.

How to Store and Dispose of Престанс Н?

This section outlines the official, regulated storage and disposal requirements for Престанс Н.

Storage and Stability Requirements	Official Mandates
Temperature and Environment	Store the medicinal product below 30 C.
Container Protection	Keep the blister in the outer carton to protect the tablets from light and moisture.
Product Integrity	Do not use this medicine after the expiry date stated on the carton and blister.
Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Official disposal regulations specify that unused or expired Престанс Н must not be disposed of via household waste or wastewater. To help protect the environment, return any unused medicine or waste material to a pharmacist or pharmacy, in accordance with local requirements.